Uniferon in all Nordic countries

April 11, 2012

With the successful launch in Sweden, Uniferon is now available in all Nordic countries.

Denmark, Sweden, Norway and Finland are recognized for having some of the most demanding pig producers in the world, and the presence of Uniferon on these strategically important markets marks a significant step in our global endeavours.

The availability of Uniferon also ensures a short distance between Pharmacosmos and our customers, and it enables us to produce and deliver the best quality across borders.

International Sales Manager Christian von der Recke is very pleased with this recent progress: "Our presence in all Nordic countries is a testament to not least our partners' diligent work in the region, and it bodes extremely well for the future development of these important markets. And with one entrance to the entire region we can maintain and ensure a continued delivery of high quality iron to the pig farmers."

About Uniferon

Uniferon is a modern improved iron hydrogenated dextran based on a natural formula, which is approved for global use:

Uniferon is manufactured without the use of any organic solvents or cyanide, thus, avoiding trace residues of these impurities. Pharmacosmos manufactures iron dextran of high quality and unique purity for customers worldwide. Uniferon is the only injectable iron brand for piglets approved in the EU, the US and Asia.

About Pharmacosmos

Headquartered in Denmark, Pharmacosmos is a family-owned, international healthcare company with more than 50 years of innovation and leadership in iron- and carbohydrate-based treatments and solutions for human and animal use.

A research-based company, its ongoing R&D programme focuses on improving the lives of patients with iron deficiency with or without anaemia. More than 1 billion people live with iron deficiency anaemia and it is the leading cause of death for an estimated 180,000 people every year. This makes it one of the largest global health challenges of our time.

Pharmacosmos has subsidiaries in the Nordics, the UK and the US and its products are marketed in more than 80 countries across the world. Its manufacturing facilities are approved, among others, by the Danish Medicines Agency and the US FDA.